The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.
Westchester Medical Center today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center, whose staff will provide outpatient cancer care and infusion services.
IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.
A new pancreatic cancer research center has been created at Memorial Sloan Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.
Prostate cancer patients who are prescribed oral erectile medication before and after radiation therapy have improved sexual function, according to a research team at Memorial Sloan Kettering Cancer Center.
New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations. The study, led by Memorial Sloan Kettering Cancer Center biostatistician Chaya Moskowitz, PhD, was presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Researchers from Memorial Sloan Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.